Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchangedNew Treatment Options Show Promise for Specific Lymphoma Patients

Frontiers in Medicine Published June 23, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider Pola-R-CHP as a potential first-line option for DEL, but note OS benefit is unproven and evidence is indirect.

This network meta-analysis evaluated Pola-R-CHP, Ven-R-CHOP, VR-CHOP, and CR-CHOP versus R-CHOP in 1,016 treatment-naïve patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma (DEL). The primary outcome was progression-free survival (PFS). Pola-R-CHP significantly reduced progression risk by 35% compared to R-CHOP (HR=0.65, 95% CI 0.45–0.94; SUCRA=76.1%). No regimen significantly improved overall survival; CR-CHOP showed a trend (HR=0.77, 95% CI 0.53–1.13; SUCRA=69.8%).

Safety analysis revealed that Ven-R-CHOP significantly increased grade 3–4 thrombocytopenia, neutropenia, and anemia, while Pola-R-CHP had a comparable safety profile to R-CHOP (any grade 3–4 AE: OR=1.04). The authors note that the evidence is indirect, based on subgroup-level data, and of moderate-to-low certainty due to the lack of head-to-head trials specifically in DEL.

Practice relevance: Pola-R-CHP may offer a favorable benefit–risk profile in DEL, but prospective confirmation is needed. Clinicians should interpret these findings cautiously given the indirect nature of the comparisons and the absence of significant OS benefit.

How this fits prior evidence

This network meta-analysis extends prior findings on tafasitamab plus lenalidomide and R-CHOP in high-risk DLBCL by evaluating Pola-R-CHP specifically in the double-expressor subtype. It contrasts with venetoclax-based combinations in CLL, which showed superior PFS versus chemoimmunotherapy, as no venetoclax-containing regimen significantly improved OS in DEL. The analysis addresses a gap by focusing on a molecularly defined subgroup, but the indirect evidence is of moderate-to-low certainty.

Researchers analyzed data from 1,016 patients with a specific type of lymphoma called MYC/BCL2 double-expressor diffuse large B-cell lymphoma (DEL). They compared several treatment combinations, including Pola-R-CHP and Ven-R-CHOP, against the standard R-CHOP treatment.

The analysis found that the Pola-R-CHP regimen significantly reduced the risk of disease progression by 35% compared to the standard treatment. However, the study did not find any of the tested regimens significantly improved overall survival rates for patients.

Safety is an important consideration in these treatments. While Pola-R-CHP had a safety profile similar to the standard treatment, the Ven-R-CHOP regimen was linked to higher rates of low blood counts, such as anemia and neutropenia. Because this study used indirect evidence from different trials rather than direct head-to-head comparisons, the results are considered to have moderate to low certainty. Patients should talk to their doctors about how these findings might apply to their specific situation.

What this means for you:

One treatment combination showed a lower risk of progression, but it did not show better overall survival rates.

Common questions

Does Pola-R-CHP improve survival for lymphoma patients?

The study found that while Pola-R-CHP significantly reduced the risk of disease progression by 35% compared to R-CHOP, it did not show a significant improvement in overall survival rates. Because the evidence is based on indirect comparisons, these results should be discussed with a doctor.

Are there side effects associated with these treatments?

The Pola-R-CHP treatment had a safety profile similar to the standard R-CHOP. However, the Ven-R-CHOP regimen was linked to higher rates of grade 3 or 4 thrombocytopenia, neutropenia, and anemia. You should talk to your medical team about which risks are most relevant to you.

How certain are these results for DEL patients?

The evidence is considered to have moderate to low certainty because the study used indirect comparisons rather than direct head-to-head trials. While Pola-R-CHP showed a favorable benefit-risk profile, it still requires confirmation through future prospective studies.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

Double-expressor lymphoma (DEL), characterized by concurrent overexpression of MYC and BCL2 without gene rearrangements, represents 20%–30% of DLBCL and confers inferior outcomes with standard R-CHOP. However, no head-to-head trials comparing novel R-CHOP-based regimens specifically in DEL exist. We conducted a frequentist network meta-analysis to compare four modified R-CHOP regimens in treatment-naïve DEL patients. PubMed, EMBASE, Cochrane Library, and Web of Science were searched through December 2025. The efficacy analysis included four studies (CAVALLI, DEB, POLARIX, Randomised Evaluation of Molecular guided therapy for Diffuse Large B-cell lymphoma with Bortezomib (REMoDL-B); 1,016 DEL patients) evaluating Pola-R-CHP, Ven-R-CHOP, VR-CHOP, and CR-CHOP versus R-CHOP in a star-shaped network in which all interexperimental comparisons are purely indirect through the common R-CHOP comparator. For progression-free survival (PFS), Pola-R-CHP was the only regimen achieving statistical significance (HR = 0.65, 95% CI = 0.45–0.94; SUCRA = 76.1%), reducing progression risk by 35%. A supplementary Bayesian analysis confirmed this finding (posterior probability of HR < 1: 90.2%). No regimen significantly improved overall survival (OS). CR-CHOP showed the most favorable OS trend (HR = 0.77, 95% CI = 0.53–1.13; SUCRA = 69.8%). Safety analysis from intention-to-treat populations revealed that Ven-R-CHOP significantly increased grade 3–4 thrombocytopenia (OR = 17.24), neutropenia (OR = 3.42), and anemia (OR = 3.29), whereas Pola-R-CHP demonstrated a safety profile comparable to R-CHOP (any grade 3–4 AE: OR = 1.04). Sensitivity analyses excluding CAVALLI (historical control design), using alternative DEL definitions for REMoDL-B, and excluding REMoDL-B confirmed robustness. Pola-R-CHP may offer a favorable benefit–risk profile in DEL; however, this is based on indirect, subgroup-level evidence of moderate-to-low certainty, and prospective DEL-specific trials are needed for confirmation. The study protocol was registered on INPLASY (registration number: INPLASY202630036; DOI: 10.37766/inplasy2026.3.0036).

Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchangedNew Treatment Options Show Promise for Specific Lymphoma Patients

How this fits prior evidence

Common questions

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchangedNew Treatment Options Show Promise for Specific Lymphoma Patients

How this fits prior evidence

Common questions

More on Diffuse Large B-Cell Lymphoma

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties